Another selective estrogen-receptor modulator for osteoporosis.
Becker
Carolyn
C
D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000453:epidemiology / Q000517:prevention & control; D003327:Coronary Disease / Q000517:prevention & control; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control*; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy*; D011759:Pyrrolidines / Q000009:adverse effects / Q000627:therapeutic use*; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D012306:Risk; D020845:Selective Estrogen Receptor Modulators / Q000009:adverse effects / Q000627:therapeutic use*; D016103:Spinal Fractures / Q000453:epidemiology / Q000517:prevention & control*; D020521:Stroke / Q000517:prevention & control; D013629:Tamoxifen / Q000627:therapeutic use; D013764:Tetrahydronaphthalenes / Q000009:adverse effects / Q000627:therapeutic use*; D054556:Venous Thromboembolism / Q000139:chemically induced
D050071:Bone Density Conservation Agents; D011759:Pyrrolidines; D020845:Selective Estrogen Receptor Modulators; D013764:Tetrahydronaphthalenes; D013629:Tamoxifen; C111332:Lasofoxifene; D020849:Raloxifene Hydrochloride